These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Rappa G; Lorico A; Liu MC; Kruh GD; Cory AH; Cory JG; Sartorelli AC Biochem Pharmacol; 1997 Sep; 54(6):649-55. PubMed ID: 9310341 [TBL] [Abstract][Full Text] [Related]
5. Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells. Somerville L; Cory JG Anticancer Res; 2000; 20(5B):3347-55. PubMed ID: 11131634 [TBL] [Abstract][Full Text] [Related]
6. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells. Carter GL; Cory JG Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392 [TBL] [Abstract][Full Text] [Related]
7. 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, a second-generation antineoplastic agent of the alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazone series. Agrawal KC; Schenkman JB; Denk H; Mooney PD; Moore EC; Wodinsky I; Sartorelli AC Cancer Res; 1977 Jun; 37(6):1692-6. PubMed ID: 870183 [TBL] [Abstract][Full Text] [Related]
8. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563 [TBL] [Abstract][Full Text] [Related]
9. Liver microsomal inactivation of 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone as an inhibitor of ribonucleotide reductase. Williams MT; Simonet L; Cory AH; Cory JG Cancer Res; 1988 Nov; 48(22):6375-8. PubMed ID: 3052801 [TBL] [Abstract][Full Text] [Related]
10. Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to various kinase inhibitors. Somerville L; Cory JG Anticancer Res; 1999; 19(2A):1021-6. PubMed ID: 10368649 [TBL] [Abstract][Full Text] [Related]
11. Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase. Carter GL; Cory JG Adv Enzyme Regul; 1989; 29():123-39. PubMed ID: 2699151 [TBL] [Abstract][Full Text] [Related]
12. Effect of doxorubicin on wild-type and deoxyadenosine-resistant mouse leukemia L1210 cells. He AW; Cory JG Int J Oncol; 1999 May; 14(5):891-5. PubMed ID: 10200338 [TBL] [Abstract][Full Text] [Related]
13. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors. Cory JG; Carter GL Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399 [TBL] [Abstract][Full Text] [Related]
14. Relationships between sensitivity to hydroxyurea and 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone (MAIO) and ribonucleotide reductase RNR2 mRNA levels in strains of Saccharomyces cerevisiae. Rittberg DA; Wright JA Biochem Cell Biol; 1989 Jul; 67(7):352-7. PubMed ID: 2675933 [TBL] [Abstract][Full Text] [Related]
15. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Cory JG; Cory AH; Rappa G; Lorico A; Liu MC; Lin TS; Sartorelli AC Biochem Pharmacol; 1994 Jul; 48(2):335-44. PubMed ID: 8053929 [TBL] [Abstract][Full Text] [Related]